Relative Dose Intensity of Chemotherapy and Survival of Early-Stage Breast Cancer Patients at Maharat Nakhonratchasima Hospital
Article Sidebar
Main Article Content
Abstract
Objectives: To study the relationship between relative dose intensity (RDI) of standard chemotherapy regimen and survival among early-stage breast cancer patients receiving adjuvant chemotherapy. Methods: This research was a retrospective cohort study in early-stage breast cancer patients who had undergone surgery and received the first adjuvant chemotherapy at Maharat Nakhon Ratchasima Hospital. Chemotherapy doses received by patients retrieved from hospital electronic medical record were used to calculate RDI. The study evaluated treatment outcomes of those with RDI < 85% and those with RDI > 85% for a period of 5 years. The study utilized the Cox proportional hazards model to analyze hazard ratio of mortality, recurrence, and adverse event. Results: A total of 601 patients were included in the study. There were 151 patients (25.12%) in the RDI < 85% group and 450 patients (74.88%) in the RDI > 85% group. Patients with RDI > 85% had lower hazard ratio of mortality (HR of 0.66; 95% CI 0.41, 1.06) but not statistically significant. In addition, there were no statistically significant differences between groups in terms of hazard ratio of recurrence, hematologic toxicity and cardiovascular toxicity. Conclusions: Among early stage breast cancer patients who were treated with surgery and adjuvant chemotherapy of RDI < 85% and RDI > 85%, there were no statistically significant differences in hazard ratio of mortality, recurrence, and adverse events.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
ผลการวิจัยและความคิดเห็นที่ปรากฏในบทความถือเป็นความคิดเห็นและอยู่ในความรับผิดชอบของผู้นิพนธ์ มิใช่ความเห็นหรือความรับผิดชอบของกองบรรณาธิการ หรือคณะเภสัชศาสตร์ มหาวิทยาลัยสงขลานครินทร์ ทั้งนี้ไม่รวมความผิดพลาดอันเกิดจากการพิมพ์ บทความที่ได้รับการเผยแพร่โดยวารสารเภสัชกรรมไทยถือเป็นสิทธิ์ของวารสารฯ
References
World Health Organization. Cancer prevention and control [online] .2021 [cited May 23, 2021]. Availa ble from: www.who.int/nmh/a5816/en/.
National Cancer Institute. Hospital-based cancer registry 2019 [online]. 2021 [cited May 23, 2021]. Available from: www.nci.go.th/th/File_download/Nci %20Cancer%20Registry/Hospital-Based%202019% 20NCI.pdf
Laoitthi P, Parinyanitikul N. Breast cancer: epidemio logy prevention and screening recommendations. Chulalongkorn Medical Journal 2016; 60: 497-507.
Denduluri N, Patt DA, Wang Y, Bhor M, Li X, Favret AM, et al. Dose delays, dose reductions, and relative dose intensity in patients with cancer who received adjuvant or neoadjuvant chemotherapy in community oncology practices. J Natl Compr Canc Netw 2015; 13: 1383–93.
Shayne M, Crawford J, Dale DC, Culakova E, Lyman GH. Predictors of reduced dose intensity in patients with early-stagebreast cancer receiving adjuvant chemotherapy. Breast Cancer Res Treat 2006; 17: 255-62.
Rosner B. Fundamentals of biostatistics. 5th ed. Pacific Grove, CA: Duxbery; 2000.
Denduluri N, Patt D, Wang Y, Bhor M, Li X, Favret AM, et al. Chemotherapy dose intensity and overall survival among patients with advanced breast or ovarian cancer. Clin Breast Cancer 2018; 18: 380-86.
Loibl S, Skacel T, Nekljudova V, Luck HJ, Schwenkglenks M, Brodowicz T. Evaluating the impact of relative total dose intensity (RTDI) on patients’ short and long-term outcome in taxane- and anthracycline-based chemotherapy of metas tatic breast cancer pooled analysis. BMC Cancer 2011; 11: 131. doi: 10.1186/1471-2407-11-131
Schraa SJ, Frerichs KA, Agterof MJ, Hunting JCB, LosM, Jong PCD. Relative dose intensity as a proxy measure of quality andprognosis in adjuvant chemotherapy for breast cancer in daily clinical practice. Eur J Cancer B Oral Oncol 2017; 79: 152-57.
Ladwa R, Kalas T, Pathmanathan S, Woodward N, Wyld D, Sanmugarajah J. Maintaining dose intensity of adjuvant chemotherapy in older patients with breast cancer. Clin Breast Cancer 2018; 18: 1181–7.
Bonadonna G. Valagussa P, Moliterni A: Adjuvant cyclophosphamide, methotrexate and fluorouracil in node positive breast cancer. New Engl J Med 1995, 14: 901-16.
Curigliano G, Cardinale D, Suter T, Plataniotis G, Azambuja ED, Sandri MT, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: Ann Oncol 2012; 7: 155-66.
Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013; 381: 805-16.
Hershman DL, Shao T, Kushi LH, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 2011; 126: 529–37.
